Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Patch test checks skin safety of 18 different transdermal patches

NCT ID NCT07060976

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study tested the safety of 18 different skin patches on 26 healthy adults. Patches were applied for 24 hours and skin reactions like redness and swelling were checked. The goal was to see if the patches cause irritation, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transdermal patches (including capsaicin and diclofenac)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

Jul 2025

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 18-65 years (both inclusive) at the time of consent. 2. Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females). 3. Subject with normal Fitzpatrick skin type III to V (Human skin colour determination scale). 4. Females of childbearing potential must have a self-reported negative pregnancy test. 5. Subject who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results. 6. Subject is in good general health as determined by the Investigator on the basis of medical history. 7. Subjects is willing to maintain the test patches in designated positions for 24 Hours. 8. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits. 9. Subject must be able to understand and provide written informed consent to participate in the study. 10. Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given. 11. For Sensitive Specific Skin Study Only: * Subject scoring greater than 30 for Section 2 - Sensitive v/s Resistant skin in modified Dr Baumann's\* skin type questionnaire. * Subject with sensitive skin as confirmed by Lactic Acid Stinging Test. Exclusion Criteria: 1. Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading. 2. Medication which may affect skin response and/or past medical history. 3. Subject having history of diabetes 4. Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months. 5. Subject suffering from any active clinically significant skin diseases which may contraindicate. 6. Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer. 7. Participation in any patch test for irritation or sensitization within the last four weeks. 8. Subject having history of asthma or COPD (Chronic obstructive pulmonary disease). 9. Use of any: i. Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application. ii. Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and/or eye drops are permitted) 10. Topical drugs used at application site. 11. Subject with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous. 12. Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk. 13. Subject with known allergy or sensitization to medical adhesives, bandages. 14. Participation in other patch study simultaneously.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NovoBliss Research Private Limited

    Ahmedabad, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.